Discussion board discusses how international pharma can empower China’s public well being system

Discussion board discusses how international pharma can empower China’s public well being system

A blue paper on China”s public well being and epidemic prevention is launched on the fifth China Worldwide Import Expo on Nov 5, 2022. [Photo provided to chinadaily.com.cn]

A discussion board about China’s public well being and epidemic prevention efforts was held on the opening day of the fifth China Worldwide Import Expo in Shanghai on Nov 5.

Through the occasion, contributors from the CIIE Bureau and members of the CIIE Public Well being Epidemic Prevention Particular Committee mentioned how international pharma firms may coordinate assets and collaborate in order to empower China’s public well being system.

“The CIIE is dedicated to making a platform to facilitate communication between authorities departments and enterprises. We anticipate all of the efforts to drive improvement and enhance public well-being,” stated Liu Fuxue, deputy director common of the CIIE Bureau.

“The Corridor of Medical Gear and Healthcare Merchandise has been a characteristic ever for the reason that inaugural CIIE in 2018. We then arrange an space devoted to public well being and epidemic prevention on the third CIIE. We hope that every one events concerned may share assets and promote communication and collaboration to empower China’s public well being system.”

Jean-Christophe Pointeau, China president for Pfizer International Biopharma Enterprise, stated the CIIE has proved to be a worthwhile platform for exhibition and communication to boost joint efforts to optimize the general public well being and epidemic prevention system.

Throughout final yr’s CIIE, Pfizer’s antiviral oral therapeutic drug for COVID-19 Paxlovid made its debut in China. Earlier this yr, the drug was granted approval in China as authorities optimized drug overview and approval procedures.

“China has opened new floor for its public well being system by introducing progressive reform on drug approval procedures. This has additionally introduced super alternatives for enterprise improvement,” stated Pointau. “With the approval of the Chinese language authorities, Paxlovid is now lined underneath reimbursement schemes in lots of locations, permitting Chinese language sufferers to learn from this breakthrough innovation along with different individuals on the earth. That is the very best proof of win-win collaboration.”

A blue paper on China’s public well being and epidemic prevention was additionally launched on the discussion board. The paper, compiled by the particular committee, took an in-depth take a look at six firms – Pfizer, Siemens Healthineers, Johnson & Johnson, Abbott, BioMerieux and PerkinElmer – and the way their investments, greatest practices, improvements, company social duty and strategic agendas in China can be utilized as a reference to boost China’s public well being system.

The CIIE Public Well being Epidemic Prevention Particular Committee was established in June 2020 to facilitate exchanges about cutting-edge public well being and epidemic prevention merchandise, applied sciences and providers.

PUBLIC HEALTH